Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss
Michel Engeln, Stefania Fasano, Serge H. Ahmed, Martine Cador, Veerle Baekelandt, Erwan Bézard, Pierre‐Olivier Fernagut
Abstract
Open-access reader
Michel Engeln, Stefania Fasano, Serge H. Ahmed, Martine Cador, Veerle Baekelandt, Erwan Bézard, Pierre‐Olivier Fernagut
Abstract
Open-access reader
Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α-synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients.
OpenAlex reports 47 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α-synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients.
Key concepts: Levodopa, Dopaminergic, Neuroscience, Parkinson's disease, Medicine, Dopamine, Pharmacology, Psychology